Preeclampsia: pathophysiology, diagnosis, and management.
Preeclampsia, a major cause of fetal and maternal morbidity and mortality, may be difficult to distinguish clinically from other hypertensive disorders of pregnancy. Signs helpful in its diagnosis include presentation during late gestation in a nullipara with edema and proteinuria, and one or more of the following: hemoconcentration, hypoalbuminemia, liver function and/or coagulation abnormalities, and increased urate levels. Measures that may prove useful in differentiating preeclampsia from less dangerous forms of hypertension are decreased antithrombin III levels, increments in serum iron and carboxyhemoglobin, and decreases in urinary calcium. Major pathophysiological features of preeclampsia are decreased cardiac output, pulmonary capillary wedge pressure, and plasma volume; and marked increases in peripheral vascular resistance, as well as exaggerated pressor responses to endogenous angiotensin II and catecholamines. Renal hemodynamics decrease, in part as a result of a characteristic morphological lesion in glomeruli ("endotheliosis"), and there may be increased vascular permeability leading to albumin loss from the intravascular space. When gestation is advanced, termination is the treatment of choice; when temporization is required, several antihypertensive medications whose safety and efficacy have been tested in pregnant women are available. Magnesium sulfate remains the drug of choice for impending convulsions (the eclamptic phase of the disease). Finally, the etiology of preeclampsia remains unknown, but a popular theory suggests that alterations in prostaglandin metabolism may be responsible for the hypertension and coagulopathy in this disorder. In this respect, prophylactic treatment with low doses of aspirin, which decrease platelet thromboxane production but spare endothelial prostacyclin release, may decrease the incidence of preeclampsia in "high-risk" populations.
Lindheimer
M D
MD
Department of Medicine, University of Chicago, Pritzker School of Medicine, Illinois 60637.
Katz
A I
AI
D000959:Antihypertensive Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D015232:Dinoprostone / Q000502:physiology; D004461:Eclampsia / Q000517:prevention & control; D005260:Female; D006439:Hemodynamics; D006801:Humans; D008278:Magnesium Sulfate / Q000627:therapeutic use; D011225:Pre-Eclampsia / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D011247:Pregnancy
D000959:Antihypertensive Agents; D008278:Magnesium Sulfate; D015232:Dinoprostone